738: Developing a therapeutic for the most vulnerable in the first 48 hours of testing positive for the coronavirus. Armand Balboni, MD, PhD CEO Appili Therapeutics. Canada TSX: APLI. US OTC: APLIF
Photo: No known restrictions on publication.1917. Canada, Nova Scotia, Halifax--View of waterfront http://JohnBatchelorShow.com/contact http://JohnBatchelorShow.com/schedules Parler & Twitter: @BatchelorShow Developing a therapeutic for the most vulnerable in the first 48 hours of testing positive for the coronavirus. Armand Balboni, MD, PhD CEO Appili Therapeutics. Canada TSX: APLI. US OTC: APLIF https://www.appilitherapeutics.com/business-environment Armand Balboni, MD, PhD Chief Executive Officer Armand Balboni's career includes medical research and drug development experience in civilian, academic and military organizations, most recently as a partner at Bloom Burton & Co. where he was the firms senior advisor for regulatory and medical affairs. As an active duty military officer, Dr. Balboni served as a staff officer at the U.S. Army Research Institute of Infectious Diseases (USAMRIID). He completed a military staff fellowship at the U.S. Food and Drug Administration and went on to serve as the deputy director of clinical and regulatory affairs for the U.S. Army. Armand completed his doctoral work in the MD/PhD program at the Icahn School of Medicine at Mount Sinai and earned his law degree at Brooklyn Law School. .